You are here: Industry Insights > Amgen

News List

Amgen wins court patent ruling over Sandoz biosimilar europeanpharmaceuticalreview
August 14, 2019
The US District Court has decided in favour of Amgen’s Enbrel, ruling over Sandoz’s Erelzi in a patent conflict.
With Enbrel patent victory, Amgen scores major win against biosims—and Sandoz takes a big loss fiercepharma
August 13, 2019
Enbrel, its top-selling product, has steered clear of a major stumbling block, thanks to a victory in patent court that kicks potential biosimilars years down the road.
US court rules in favour of Amgen in Enbrel patent case pharmaceutical-technology
August 13, 2019
The US District Court for the District of New Jersey has upheld two of Amgen’s patents that claim its rheumatoid arthritis drug Enbrel (etanercept) and methods for making the medicine.
Amgen sales slide as copies dig into Sensipar, Neulasta firstwordpharma
August 01, 2019
Amgen is contending with some costly losses of exclusivity, and as sales for old stalwarts slide, the drugmaker is shifting its focus to a host of new launches in a bid to grow down the line.
Enbrel and Its Patent Layout: The Period of Market Exclusivity until 2029! PharmaSources/zhixing
July 30, 2019
Patents are fortresses of new drugs. The patent layout of Enbrel is quite impressive: the span from the first application in 1995 to the patent expiration in 2029 reaches 34 years.
Amgen and Novartis discontinue Alzheimer’s drug development programme pharmaceutical-technology
July 17, 2019
Amgen and Novartis have announced the discontinuation of their clinical development programme for CNP520 (umibecestat), a BACE1 inhibitor for Alzheimer’s disease, which the Arizona-based Banner Alzheimer’s Institute was also supporting.
Amgen, Novartis, Banner Alzheimer's Institute Discontinue CNP520 Clinical Research americanpharmaceuticalreview
July 16, 2019
Amgen, Novartis, and Banner Alzheimer's Institute announced the collective decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in ...
Amgen wins patent block on Sanofi drug rival drugs
July 16, 2019
Amgen has successfully blocked the manufacture, sales and marketing of its Sanofi drug rival in Germany.
Amgen, Novartis and Banner Discontinue CNP520 in AD contractpharma
July 15, 2019
An assessment of data identified worsening in some measures of cognitive function.
Amgen ready to kick PCSK9 rivals Sanofi, Regeneron off the market in Germany fiercepharma
July 13, 2019
Amgen and its PCSK9 rivals Sanofi and Regeneron have been battling over U.S. patents for years, but this week Amgen scored a win in Germany—and it's the sort of win the company would like to duplicate in the U.S.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page